Action of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide on the rat vascular system: effects on blood pressure and receptor binding

in Journal of Endocrinology
Authors:
K. A. Nandha
Search for other papers by K. A. Nandha in
Current site
Google Scholar
PubMed
Close
,
M. A. Benito-Orfila
Search for other papers by M. A. Benito-Orfila in
Current site
Google Scholar
PubMed
Close
,
D. M. Smith
Search for other papers by D. M. Smith in
Current site
Google Scholar
PubMed
Close
,
M. A. Ghatei
Search for other papers by M. A. Ghatei in
Current site
Google Scholar
PubMed
Close
, and
S. R. Bloom
Search for other papers by S. R. Bloom in
Current site
Google Scholar
PubMed
Close
Restricted access
Rent on DeepDyve

Sign up for journal news

ABSTRACT

The N-terminal fragment (PACAP 27) of the novel neuropeptide, pituitary adenylate cyclase-activating polypeptide 38 (PACAP 38), has 68% homology with vasoactive intestinal polypeptide (VIP). The administration of bolus doses of PACAP 38 and its 27 amino acid N-terminal fragment (PACAP 27) caused a rapid but transient dose-dependent hypotensive effect in the anaesthetized rat. The amplitude and duration of the response obtained by PACAP 38 was comparable with VIP whereas PACAP 27 was three times less potent than VIP. Furthermore, radioreceptor binding studies demonstrated that 125I-labelled PACAP 27 and 125I-labelled VIP bound to membranes prepared from blood vessels. Both PACAP 27 and VIP were capable of displacing the other from these binding sites. We propose that the hypotensive effect is via the same receptor type.

Journal of Endocrinology (1991) 129, 69–73

 

  • Collapse
  • Expand